Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Fagron realises organic turnover growth of 6.8%

Fagron NV
Posted on: 12 Apr 18

Regulated information
Nazareth (Belgium) / Rotterdam (The Netherlands), 12 April 2018

Fagron realises organic turnover growth of 6.8%

Key points

  • Organic turnover growth in Europe, South America and North America.
  • Europe: Structural solution to limited availability of pharmaceutical raw materials
  • South America: Innovation-driven growth of Brands
  • North America:
    • Wichita facility receives licence California
    • Complementary acquisition of the American company Humco
    • Settlement with former owners of JCB Laboratories
  • Further growth in turnover and profitability expected in 2018


Rafael Padilla, CEO of Fagron : "Fagron reported strong results in the first quarter of 2018. The comparable turnover at constant exchange rates increased by 6.8%. Turnover growth was supported by all regions we are active in. Although turnover growth in Europe was still affected by limited product availability of pharmaceutical raw materials in the first quarter, this problem has now largely been solved. We expect that with the structural solution, turnover development will no longer be negatively affected in the current quarter.

The focus on the development and introduction of innovative products, and particularly the introduction of lifestyle-related prescription products in Brazil, has led to significant growth at Brands in the first quarter of 2018.

In North America, the compounding facility in Wichita (Kansas) has been operational now for a full year. I'm pleased to announce that we received a licence for California, the most important state for our sterile products, in March 2018. This 49 th licence means that the only two licences we still need to obtain, are those for Indiana and North Dakota. We expect to receive these later this year.

Besides the organic growth we realised, the in April announced acquisition of Humco - a leading developer, manufacturer and supplier of patented pharmaceutical delivery vehicles and pharmaceutical branded products - significantly and strategically strengthens our strategic position in the United States. Fagron's leading market positions combined with the acquisition of Humco give us an excellent proposition for further growth of turnover as well as profitability in 2018."

Turnover (x € 1,000)Q1 2018 Q1 2017 [1] Total growthTotal growth CEROrg. growthOrg. growth CER
Fagron Europe63,52462,2102.1%1.5%4.3%3.7%
Fagron South America23,84625,111-5.0%13.1%-9.8%7.4%
Fagron North America19,97219,995-0.1%15.3%-0.1%15.3%
Fagron (excl. HL Technology) 107,342 107,317 0.0% 6.8% 0.0% 6.8%
HL Technology1,7291,7230.4%9.4%0.4%9.4%
Fagron Group 109,071 109,040 0.0% 6.8% 0.0% 6.8%

CER = constant exchange rates

Please open the link below for the press release:

Fagron realises organic turnover growth of 6.8%

[1] Turnover of 2017 is revised for IFRS 15.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Fagron NV via GlobeNewswire

Last updated on: 13/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.